"I reckon that if there was any hint on the current phase 3 trials not panning out they would not be aggressively pursuing global licensing deals, nor would Advanz Pharma have gone ahead with entering into a deal and parting with $10.8 million straight up"
Absolutely! Management knows it is efficacious from Stage 2a. That's why Nina so enthusiastically responded to the Stocks Down Under interviewer that champagne and popping corks will be in readiness for March 15.
They just need the Phase 3 interim read-out to demonstrate that the efficacy is also statistically significant.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |